| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.070 | Biomarker | phenotype | BEFREE | We subjected our ALK TKI-refractory cancer cells along with parental cancer cells to systematic miRNA expression arrays. | 30791979 | 2019 | ||||
|
0.070 | GeneticVariation | phenotype | BEFREE | While few of the mechanisms of clinical resistance to ALK inhibitors such as gene mutation are well known, there are others that are not well covered. | 29143801 | 2017 | ||||
|
0.070 | GeneticVariation | phenotype | BEFREE | Early data point to <i>ALK</i> G1202R and <i>ALK</i> E1210K as potential mechanisms of clinical resistance to brigatinib. | 28435288 | 2017 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | Therefore, c-Met overexpression, HER-2 gene amplification, and SPTBN1-ALK gene fusion can coexist in lung adenocarcinoma and may become a potential biomarker of cancer refractory to crizotinib, chemotherapy, and radiotherapy as well as of a relatively poor prognosis. | 27496196 | 2016 | ||||
|
0.070 | GeneticVariation | phenotype | BEFREE | For example, the combination of ALK and MAPK kinase (MEK) inhibitors was active in an ALK-positive resistant tumor that had developed a MAP2K1 activating mutation, and the combination of EGFR and fibroblast growth factor receptor (FGFR) inhibitors was active in an EGFR mutant resistant cancer with a mutation in FGFR3. | 25394791 | 2014 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | While excellent clinical response has been observed in many patients, the acquisition of clinical resistance to ALK inhibition highlights the need for development of second-generation ALK kinase inhibitors and/or combination therapies that target downstream signaling mediators or antibody drug conjugates. | 23696342 | 2013 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | Our study identifies multiple novel mutations in ALK that may confer clinical resistance to crizotinib, suggests that crizotinib's narrow selectivity window may underlie its susceptibility to such resistance and demonstrates that a more potent ALK inhibitor may be effective at overcoming resistance. | 22034911 | 2011 |